Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
SSC5D Biologics Sequence Review Report 2026: Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of SSC5D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MEGF11 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 11 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MEGF11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLK3 Biologics Sequence Review Report 2026: Prostate-specific antigen Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of KLK3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFNW1 Biologics Sequence Review Report 2026: Interferon omega-1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNW1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFNA7 Biologics Sequence Review Report 2026: Interferon alpha-7 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFNL4 Biologics Sequence Review Report 2026: Interferon lambda-4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNL4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFNA8 Biologics Sequence Review Report 2026: Interferon alpha-8 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFNA4 Biologics Sequence Review Report 2026: Interferon alpha-4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFNA2 Biologics Sequence Review Report 2026: Interferon alpha-2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFNA21 Biologics Sequence Review Report 2026: Interferon alpha-21 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA21 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFI30 Biologics Sequence Review Report 2026: Gamma-interferon-inducible lysosomal thiol reductase Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFI30 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFNA17 Biologics Sequence Review Report 2026: Interferon alpha-17 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.